Novo Nordisk A/S (NYSE:NVO) Rating Lowered to “Strong Sell” at Zacks Research

Novo Nordisk A/S (NYSE:NVO) was downgraded by stock analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued on Monday,Zacks.com reports.

NVO has been the subject of a number of other research reports. Morgan Stanley restated an “underweight” rating and set a $42.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, December 3rd. Jefferies Financial Group began coverage on shares of Novo Nordisk A/S in a report on Monday, October 27th. They issued an “underperform” rating on the stock. Weiss Ratings upgraded shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, February 5th. TD Cowen reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 3rd. Finally, BMO Capital Markets restated a “market perform” rating on shares of Novo Nordisk A/S in a report on Thursday, February 5th. Seven equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $56.07.

Novo Nordisk A/S Trading Down 1.6%

Shares of NYSE:NVO traded down $0.80 during midday trading on Monday, reaching $48.33. The company had a trading volume of 6,352,811 shares, compared to its average volume of 25,867,979. The company has a fifty day simple moving average of $53.66 and a two-hundred day simple moving average of $53.42. The firm has a market cap of $215.77 billion, a price-to-earnings ratio of 13.93 and a beta of 0.67. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. Novo Nordisk A/S has a 1-year low of $43.08 and a 1-year high of $93.80.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.11. The business had revenue of $12.43 billion during the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. Research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Hedge Funds Weigh In On Novo Nordisk A/S

Several hedge funds have recently made changes to their positions in the business. Revolve Wealth Partners LLC increased its stake in Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after buying an additional 200 shares during the last quarter. AQR Capital Management LLC grew its holdings in shares of Novo Nordisk A/S by 21.0% in the 1st quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock valued at $4,312,000 after acquiring an additional 10,758 shares in the last quarter. Sivia Capital Partners LLC increased its position in shares of Novo Nordisk A/S by 18.2% in the second quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock valued at $712,000 after acquiring an additional 1,587 shares during the last quarter. CWM LLC raised its holdings in Novo Nordisk A/S by 37.1% during the second quarter. CWM LLC now owns 107,998 shares of the company’s stock worth $7,454,000 after acquiring an additional 29,246 shares in the last quarter. Finally, Yousif Capital Management LLC boosted its position in Novo Nordisk A/S by 7.0% during the second quarter. Yousif Capital Management LLC now owns 38,849 shares of the company’s stock valued at $2,681,000 after purchasing an additional 2,553 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: CEO Mike Doustdar highlighted a potential ~15 million-patient addressable market if Medicare begins covering obesity treatments, signaling substantial long-term upside if access expands. Novo Nordisk CEO sees 15 million-patient opportunity in Medicare coverage for obesity drugs
• Positive Sentiment: Novo sued Hims & Hers for alleged patent infringement over Hims’ low‑cost Wegovy copy, a defensive step to protect pricing and market share for Wegovy/Ozempic. Legal action can limit copycat competition if successful. Novo Nordisk opens new front with patent suit over Hims’ Wegovy copies
• Positive Sentiment: Hims & Hers pulled compounded semaglutide products after FDA warnings and related litigation pressure, removing a low-price competitor and briefly supporting Novo’s position. Novo Nordisk Rallies 3.6% as Hims & Hers Pulls Compounded Semaglutide
• Neutral Sentiment: Insiders and executives reported share transactions; trading by insiders is disclosed but not necessarily directional for fundamentals. Trading in Novo Nordisk shares by board members, executives and associated persons
• Neutral Sentiment: Heightened media and retail attention is keeping NVO in focus; trending coverage can amplify moves but doesn’t change fundamentals by itself. Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
• Negative Sentiment: Investors punished NVO after management issued weak 2026 guidance citing US price declines and slower Ozempic/Wegovy sales — the primary driver of the recent drop in valuation. Is Novo Nordisk’s Turnaround Story at Risk After Weak 2026 Outlook?
• Negative Sentiment: Analysts cut targets and ratings (Deutsche Bank trimmed its price target ~16%; Zacks moved to a “strong sell”), amplifying selling pressure and signaling lowered expectations. Novo Nordisk target cut by Deutsche Bank despite long-term optimism Zacks downgrade coverage
• Negative Sentiment: Regulatory scrutiny—an FDA finding that a TV ad for the Wegovy pill contained misleading claims—adds reputational and marketing risk at a sensitive time. Novo’s TV ad for Wegovy pill had misleading claims, FDA says

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.